Cleaved high-molecular-weight kininogen inhibits neointima formation following vascular injury

Summary

Cleaved high-molecular-weight kininogen (HKa) or its peptide domain 5 (D5) alone exert anti-adhesive properties in vitro related to impeding integrin-mediated cellular interactions. However, the anti-adhesive effects of HKa in vivo remain elusive. In this study, we investigated the effects of HKa on leukocyte recruitment and neointima formation following wire-induced injury of the femoral artery in C57BL/6 mice. Local application of HKa significantly reduced the accumulation of monocytes and also reduced neointimal lesion size 14 days after injury. Moreover, C57BL/6 mice transplanted with bone marrow from transgenic mice expressing enhanced green fluorescence protein (eGFP) showed a significantly reduced accumulation of eGFP⁺-cells at the arterial injury site and decreased neointimal lesion size after local application of HKa or the polypeptide D5 alone. A differentiation of accumulating eGFP⁺-cells into highly specific smooth muscle cells (SMC) was not detected in any group. In contrast, application of HKa significantly reduced the proliferation of locally derived neointimal cells. In vitro, HKa and D5 potently inhibited the adhesion of SMC to vitronectin, thus impairing their proliferation, migration, and survival rates. In conclusion, application of HKa or D5 decreases the inflammatory response to vascular injury and exerts direct effects on SMC by impeding the binding of integrins to extracellular matrix components. Therefore, HKa and D5 may hold promise as novel therapeutic substances to prevent neointima formation.

Keywords

Cleaved high-molecular-weight kininogen (HKa) - cell adhesion - inflammation - smooth muscle cells - neointimal formation

• References

• 1 McBride W, Lange RA, Hillis LD. Restenosis after successful coronary angioplasty. Pathophysiology and prevention. N Engl J Med 1988; 318: 1734-1737.
• 2 Mauri L, Silbaugh TS, Wolf RE. et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008; 118: 1817-1827.
• 3 Forrester JS, Fishbein M, Helfant R. et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-769.
• 4 Weber C, Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor. J Clin Invest 1997; 100: 2085-2093.
• 5 Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: New perspectives and therapeutic strategies. Nat Med 2002; 08: 1249-1256.
• 6 Welt FG, Tso C, Edelman ER. et al. Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc Med 2003; 08: 1-7.
• 7 Sata M, Saiura A, Kunisato A. et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 08: 403-409.
• 8 Yu H, Stoneman V, Clarke M. et al. Bone marrow-derived smooth muscle-like cells are infrequent in advanced primary atherosclerotic plaques but promote atherosclerosis. Arterioscl Thromb Vasc Biol 2011; 31: 1291-1299.
• 9 Sainz IM, Pixley RA, Colman RW. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007; 98: 77-83.
• 10 Guo YL, Colman RW. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost 2005; 03: 670-676.
• 11 Chavakis T, Kanse SM, Lupu F. et al. Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood 2000; 96: 514-522.
• 12 Chavakis T, Kanse SM, Pixley RA. et al. Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J 2001; 15: 2365-2376.
• 13 Sheng N, Fairbanks MB, Heinrikson RL. et al. Cleaved high molecular weight kininogen binds directly to the integrin CD11b/CD18 (Mac-1) and blocks adhesion to fibrinogen and ICAM-1. Blood 2000; 95: 3788-3795.
• 14 Al-Fakhri N, Chavakis T, Schmidt-Woll T. et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003; 384: 423-435.
• 15 Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain. Identification of two anionic surface binding subdomains. J Biol Chem 1993; 268: 2486-2492.
• 16 Chavakis T, May AE, Preissner KT. et al. Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-inte-grins. Blood 1999; 93: 2976-2983.
• 17 Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383: 441-443.
• 18 Sedding DG, Trobs M, Reich F. et al. 3-Deazaadenosine prevents smooth muscle cell proliferation and neointima formation by interfering with Ras signaling. Circ Res 2009; 104: 1192-1200.
• 19 Daniel JM, Bielenberg W, Stieger P. et al. Time-course analysis on the differentiation of bone marrow-derived progenitor cells into smooth muscle cells during neointima formation. Arterioscl Thromb Vasc Biol 2010; 30: 1890-1896.
• 20 Sedding D, Daniel JM, Muhl L. et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 2006; 203: 2801-2807.
• 21 Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscl Thromb Vasc Biol 2002; 22: 1769-1776.
• 22 Agata J, Miao RQ, Yayama K. et al. Bradykinin B(1) receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty. Hypertension 2000; 36: 364-370.
• 23 Massberg S, Gawaz M, Gruner S. et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med 2003; 197: 41-49.
• 24 Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998; 95: 10134-10139.
• 25 Inoue T, Uchida T, Yaguchi I. et al. Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003; 107: 1757-1763.
• 26 Dufourcq P, Louis H, Moreau C. et al. Vitronectin expression and interaction with receptors in smooth muscle cells from human atheromatous plaque. Arterioscl Thromb Vasc Biol 1998; 18: 168-176.
• 27 Daniel JM, Dutzmann J, Bielenberg W. et al. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 2012; 107: 1-12.
• 28 Psaltis PJ, Harbuzariu A, Delacroix S. et al. Identification of a monocyte-predis-posed hierarchy of hematopoietic progenitor cells in the adventitia of postnatal murine aorta. Circulation 2012; 125: 592-603.
• 29 Psaltis PJ, Puranik AS, Spoon DB. et al. Characterisation of a resident population of adventitial macrophage progenitor cells in postnatal vasculature. Circ Res 2014; 115: 364-375.
• 30 Iwata H, Manabe I, Fujiu K. et al. Bone marrow-derived cells contribute to vascular inflammation but do not differentiate into smooth muscle cell lineages. Circulation 2010; 122: 2048-2057.
• 31 Daniel JM, Sedding DG. Circulating smooth muscle progenitor cells in arterial remodelling. J Mol Cell Cardiol 2011; 50: 273-279.
• 32 Colman RW, Wu Y, Liu Y. Mechanisms by which cleaved kininogen inhibits endothelial cell differentiation and signalling. Thromb Haemost 2010; 104: 875-885.
• 33 Rebuck JW. The skin window as a monitor of leukocytic functions in contact activation factor deficiencies in man. Am J Clin Pathol 1983; 79: 405-413.
• 34 Waldmann R, Abraham JP, Rebuck JW. et al. Fitzgerald factor: a hitherto unrecognised coagulation factor. Lancet 1975; 305: 949-951.